Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Paclitaxel and TAK-228 in metastatic urothelial carcinoma
2017-004486-27Phase 2Completed
- Sponsor
- SOLTI
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sapanisertib and paclitaxel in urothelial carcinoma (UC), sponsored by SOLTI. Primary endpoint: Objective Response Rate. Started Dec 2017; status: completed.
02
Drugs
sapanisertibpaclitaxel
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on 2017-004486-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004486-27.